Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen reports increased revenue for third quarter

Amgen reports increased revenue for third quarter

27th October 2008

Amgen has announced a total increase in revenue of seven per cent for the third quarter of this year, totalling $3.88 billion (2.53 billion pounds).

The results for the period demonstrate “strong operating performance” and the company will now focus on the commercialisation of its post-menopausal osteoporosis drug denosumab, said Kevin Sharer, chairman and chief executive officer of Amgen.

“We’re excited about the opportunity to bring this novel treatment option to patients with this serious disease,” he added.

During the third quarter of 2008, product sales also increased by seven per cent, reaching $3.78 billion, with certain brands increasing more than others.

Sales globally of Sensipar (cincalcet) rose by 32 per cent, while Enbrel (etanercept) went up by nine per cent. Neulasta (pegfilgrastim) and Neupogen (filgrastim) rose by eight per cent.

Earlier this month saw Amgen announce a new appointment to its board of directors.

Francois de Carbonnel will be a member of the audit, governance and nominating committees.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.